½ÃÀ庸°í¼­
»óǰÄÚµå
1532554

ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)¿ë ¼Ò¸ðǰ ½ÃÀå : Á¦Ç°, ±â¼ú, ¿ëµµ, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø

Polymerase Chain Reaction (PCR) Consumables Market, By Product, Technology, Application, End-use - Global Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)¿ë ¼Ò¸ðǰ ½ÃÀåÀº °¨¿°Áõ °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡¿Í °Ë»ç½Ç ÀÎÇÁ¶óÀÇ °³¼±¿¡ ÀÇÇØ 2024-2032³â CAGR 4.8%·Î È®´ëÇÕ´Ï´Ù.

COVID-19¿Í °°Àº °¨¿°¼º Áúȯ¿¡ ´ëÇÑ Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϸ鼭 PCR ¼Ò¸ðǰ¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÚµ¿È­ ¹× ÇÏÀ̽º·çDz ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ ½ÇÇè½Ç ÀÎÇÁ¶óÀÇ ¹ßÀüÀ¸·Î PCR °Ë»çÀÇ È¿À²¼º°ú È®À强ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Àü¹ÝÀûÀ¸·Î PCR ¼Ò¸ðǰÀÇ Ã¤Åà Ȯ´ë¿¡ ±â¿©ÇÏ°í ½ÃÀå È®´ë¿Í ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î 2024³â 4¿ù ¿¡Ææµµ¸£ÇÁ´Â ¹ÙÀÌ¿À PCR Ç÷¹ÀÌÆ®¸¦ Ãâ½ÃÇÏ¿© ½ÇÇè½ÇÀÇ Áö¼Ó°¡´É¼ºÀ» °­È­Çß½À´Ï´Ù. Æ®À©Å×Å©(R) Æ®·¹À̽º Ç÷¹ÀÌÆ®´Â ÀÚµ¿È­¿¡ ÀûÇÕÇϰí, ¹ÙÀÌ¿À ¿ø·á·Î ¸¸µé¾îÁ³À¸¸ç, 96°³ÀÇ À£ÀÌ ÀÖ°í, ¹ÝÅõ¸í Åõ¸íµµ±îÁö °®Ãß°í ÀÖÀ¸¸ç, EppendorfÀÇ Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Á¦Ç°À¸·Î Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇÔÀ¸·Î½á ¿¡Ææµµ¸£ÇÁ´Â Áö¼Ó°¡´É¼º¿¡ ´ëÇÑ ¿ì·Á¿¡ ´ëÀÀÇϰí PCR ¼Ò¸ðǰÀÇ ±â´É¼º°ú ¸Å·ÂÀ» ³ô¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ°í ¾÷°è¿¡ »õ·Î¿î ±âÁØÀ» Á¦½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦¾à»ç ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ R&D Ȱµ¿ ¾Æ¿ô¼Ò½ÌÀÌ Áõ°¡ÇÔ¿¡ µû¶ó 2032³â±îÁö CRO(À§Å¹¿¬±¸±â°ü) ºÎ¹®ÀÌ ½ÃÀå¿¡¼­ Å« ¿µÇâ·ÂÀ» ¹ßÈÖÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CRO´Â Àü¹® Áö½Ä, ÷´Ü ±â¼ú, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ÀÓ»ó½ÃÇè, ÀǾàǰ °³¹ß ¹× À¯ÀüÀÚ ¿¬±¸¿¡ ´ëÇÑ PCR ¼Ò¸ðǰ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, ÀÓ»ó½ÃÇè, ÀǾàǰ °³¹ß ¹× À¯ÀüÀÚ ¿¬±¸ ºÐ¾ß¿¡¼­ PCR ¼Ò¸ðǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. È¿À²¼ºÀ» ³ôÀ̰í ÇÙ½É ¿ª·®¿¡ ÁýÁßÇϱâ À§ÇÑ ¾Æ¿ô¼Ò½Ì Ãß¼¼´Â ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)¿ë ¼Ò¸ðǰ ½ÃÀå¿¡¼­ CROÀÇ ÀÔÁö¸¦ ´õ¿í °­È­½Ã۰í ÀÖ½À´Ï´Ù.

PCR ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ® ºÎ¹®Àº °í󸮷® Å×½ºÆ® ¹× ÀÚµ¿È­¿¡ ³Î¸® »ç¿ëµÇ¹Ç·Î 2032³â±îÁö ´«¿¡ ¶ç°Ô °³¼± µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ®´Â ¸¹Àº ¼öÀÇ »ùÇÃÀ» µ¿½Ã¿¡ ó¸®ÇÒ ¼ö ÀÖÀ¸¸ç, ½ÇÇè½ÇÀÇ È¿À²¼º°ú Á¤È®¼ºÀ» ³ôÀÔ´Ï´Ù. ´Ù¾çÇÑ PCR Àåºñ¿ÍÀÇ È£È¯¼º°ú »ç¿ë ÆíÀǼºÀ¸·Î ÀÎÇØ Áø´Ü, ¿¬±¸ ¹× ÀÓ»ó ¿ëµµ¿¡ ÇʼöÀûÀÔ´Ï´Ù. ƯÈ÷ °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ½Å¼ÓÇÏ°í ´ë±Ô¸ð °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó PCR ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ® ºÐ¾ß°¡ ´õ¿í ¹øÃ¢Çϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ PCR ¼Ò¸ðǰ »ê¾÷Àº ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í R&D¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ¿¡ ÈûÀÔ¾î 2024-2032³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)ÀÌ µÎµå·¯Áú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ÷´Ü Áø´Ü ±â¼ú äÅ÷üÀÌ ³ô°í ÁÖ¿ä »ý¸í°øÇÐ ±â¾÷ÀÇ Á¸Àç°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯Àüü ¿¬±¸¸¦ Áö¿øÇϱâ À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú Àü¿°º´ÀÇ È®»êÀ¸·Î ÀÎÇØ PCR ¼Ò¸ðǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çõ½Å°ú ÇコÄɾîÀÇ ¿ì¼ö¼ºÀ» Áß½ÃÇÏ´Â À¯·´Àº ¼¼°è ÁßÇÕÈ¿¼Ò¿¬¼â ¹ÝÀÀ(PCR) ¼Ò¸ðǰ ½ÃÀåÀÇ Áß¿äÇÑ ±â¿©ÀÚ°¡ µÉ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • °¨¿°ÁõÀÇ Áøº¸ Áõ°¡
      • ºÐÀÚÁø´Ü ¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
      • »ý¸í°úÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚÀÇ Áõ°¡
      • ½ÉÀåÆÇ¸· ¸·ÁõÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©&°úÁ¦
      • ±ÔÁ¦ ¹× ǰÁú ÄÄÇöóÀ̾𽺠¿ä°Ç
      • ¾î¼¼ÀÌ ¼³°è¿Í ÃÖÀûÈ­ÀÇ º¹À⼺
  • ¼ºÀåÀÇ °¡´É¼º ºÐ¼®
  • ±â¼úÀû Àü¸Á
  • ±ÔÁ¦ »óȲ
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç°º°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • PCR Æ©ºê
  • PCR ¸¶ÀÌÅ©·ÎÇ÷¹ÀÌÆ®
  • ĸ/¸®µå
  • ±âŸ Á¦Ç°

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ±â¼úº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ½Ç½Ã°£ PCR
  • µðÁöÅÐ PCR
  • ÀüÅëÀû PCR

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ¿¬±¸
  • ÀÓ»ó

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø, ÀÓ»ó Áø´Ü ½ÇÇè½Ç
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¡¤¿¬±¸±â°ü
  • CRO(ÀǾàǰ ÀÓ»ó½ÃÇè ¼öʱâ°ü)
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Analytik Jena AG
  • Becton, Dickinson and Company
  • Bioer Technology Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Promega Corporation
  • QIAGEN N.V.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
KSA 24.08.22

Global Polymerase Chain Reaction (PCR) Consumables Market will expand at a 4.8% CAGR between 2024 and 2032, fueled by increased focus on infectious disease management and improved laboratory infrastructure. The surge in demand for accurate and rapid diagnostic tests for infectious diseases such as COVID-19 boosts the need for PCR consumables. Moreover, advancements in laboratory infrastructure, including automation and high-throughput systems, enhance the efficiency and scalability of PCR testing. These factors collectively contribute to the growing adoption of PCR consumables, fueling market expansion and innovation.

For instance, in April 2024, Eppendorf launched BioBased PCR Plates, enhancing laboratory sustainability. The twin.tec(R) Trace Plates, automation-friendly and made from biobased feedstock, feature 96 wells and are available in translucent clear, expanding Eppendorf's portfolio. By expanding its portfolio with such innovative products, Eppendorf is addressing sustainability concerns and enhancing the functionality and appeal of PCR consumables, which could drive market growth and set new standards in the industry.

The overall polymerase chain reaction (PCR) consumables industry is divided based on product, application, end-use, and region.

The contract research organization segment will secure a noteworthy market presence by 2032, attributed to the increasing outsourcing of research and development activities by pharmaceutical and biotechnology companies. CROs offer specialized expertise, advanced technologies, and cost-effective solutions, driving their demand for PCR consumables in clinical trials, drug development, and genetic research. The growing trend of outsourcing to enhance efficiency and focus on core competencies further boosts the prominence of CROs in the polymerase chain reaction (PCR) consumables market.

The PCR microplates segment will undergo a notable upturn by 2032 due to their widespread use in high throughput testing and automation. These microplates facilitate the simultaneous processing of numerous samples, enhancing efficiency and accuracy in laboratories. Their compatibility with various PCR machines and ease of use make them essential in diagnostic, research, and clinical applications. The growing demand for rapid and large-scale testing, particularly in the context of infectious diseases, further drives the prominence of the PCR microplates segment.

Europe PCR consumables industry will record a remarkable CAGR during 2024 and 2032, propelled by advanced healthcare infrastructure and significant investment in research and development. The region's high adoption rate of advanced diagnostic technologies and the presence of leading biotechnology companies drive market growth. Additionally, government initiatives supporting genomic research and the escalating prevalence of contagious diseases bolster demand for PCR consumables. Europe's emphasis on innovation and healthcare excellence will establish it as a vital contributor to the global polymerase chain reaction (PCR) consumables market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of infectious diseases
      • 3.2.1.2 Growing demand for molecular diagnostics
      • 3.2.1.3 Rising investments in life sciences research
      • 3.2.1.4 Increasing prevalence of valvular heart diseases
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Regulatory and quality compliance requirements
      • 3.2.2.2 Complexity of assay design and optimization
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 PCR tubes
  • 5.3 PCR microplates
  • 5.4 Cap/lids
  • 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Real time PCR
  • 6.3 Digital PCR
  • 6.4 Traditional PCR

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Research
  • 7.3 Clinical

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinical diagnostic laboratories
  • 8.3 Pharmaceutical and biotechnology companies
  • 8.4 Academic and research institutes
  • 8.5 Contract research organizations (CROs)
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Analytik Jena AG
  • 10.4 Becton, Dickinson and Company
  • 10.5 Bioer Technology Co., Ltd.
  • 10.6 Bio-Rad Laboratories, Inc.
  • 10.7 Danaher Corporation
  • 10.8 F. Hoffmann-La Roche Ltd.
  • 10.9 Illumina, Inc.
  • 10.10 Merck KGaA
  • 10.11 New England Biolabs, Inc.
  • 10.12 Promega Corporation
  • 10.13 QIAGEN N.V.
  • 10.14 Takara Bio Inc.
  • 10.15 Thermo Fisher Scientific, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦